A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called ...
Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency ...
Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for ...
The U.S. Food and Drug Administration (FDA) has approved the first-ever gene therapy for inherited deafness.
Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...
Russia's Minister of Science and Education, Denis Sekirinsky, has claimed that researchers in his country are on track to ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
Providers and payers certainly face some formidable challenges when it comes to gene therapy, but it pales in comparison to ...
Seeking to make a statement on drug accessibility, the biotech giant will offer its 'groundbreaking' Otarmeni therapy at no ...
The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results